Roland Mertelsmann

Roland Mertelsmann's AcademicInfluence.com Rankings

Roland Mertelsmann

Philosophy

#5407

World Rank

#8194

Historical Rank

Logic

#2691

World Rank

#3721

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Why Is Roland Mertelsmann Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Roland Mertelsmann is a German hematologist and oncologist. He was a professor at the Freiburg University Medical Center, Department of Internal Medicine I . Mertelsmann is known for his scientific works in the fields of hematology, oncology, gene therapy and stem cell transplantation.

(See a Problem?)

Roland Mertelsmann's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Mutations Involving the Transcription Factor CBFA1 Cause Cleidocranial Dysplasia (1997) (1549)
Recombinant human granulocyte colony-stimulating factor: effects on normal and leukemic myeloid cells. (1986) (1265)
Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). (2008) (987)
Purification and biochemical characterization of human pluripotent hematopoietic colony-stimulating factor. (1985) (510)
Epidemiology of non-Hodgkin’s lymphoma (NHL): trends, geographic distribution, and etiology (2004) (467)
Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors [see comments] (1994) (410)
Effects of aerobic exercise on the physical performance and incidence of treatment-related complications after high-dose chemotherapy. (1997) (409)
Reconstitution of hematopoiesis after high-dose chemotherapy by autologous progenitor cells generated ex vivo. (1995) (381)
Constitutive activation of STAT proteins in primary lymphoid and myeloid leukemia cells and in Epstein-Barr virus (EBV)-related lymphoma cell lines. (1996) (346)
Essential role of stromally induced hedgehog signaling in B-cell malignancies (2007) (334)
Prostaglandin E2 acts at two distinct pathways of T lymphocyte activation: inhibition of interleukin 2 production and down-regulation of transferrin receptor expression. (1985) (293)
Aerobic exercise in the rehabilitation of cancer patients after high dose chemotherapy and autologous peripheral stem cell transplantation (1997) (291)
Ex vivo expansion of enriched peripheral blood CD34+ progenitor cells by stem cell factor, interleukin-1 beta (IL-1 beta), IL-6, IL-3, interferon-gamma, and erythropoietin (1993) (265)
Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors. (1994) (243)
Development of a propidium iodide fluorescence assay for proliferation and cytotoxicity assays. (1995) (238)
Presence of IgE antibodies to bovine serum albumin in a patient developing anaphylaxis after vaccination with human peptide-pulsed dendritic cells (2000) (226)
Mobilization of peripheral blood progenitor cells by sequential administration of interleukin-3 and granulocyte-macrophage colony-stimulating factor following polychemotherapy with etoposide, ifosfamide, and cisplatin. (1992) (216)
Inducible production of interleukin-6 by human polymorphonuclear neutrophils: role of granulocyte-macrophage colony-stimulating factor and tumor necrosis factor-alpha. (1990) (216)
Morphological Classification, Response to Therapy, and Survival in 263 Adult Patients With Acute Nonlymphoblastic Leukemia (1980) (214)
Neutrophil granulocytes recruited upon translocation of intestinal bacteria enhance graft-versus-host disease via tissue damage (2014) (210)
An aerobic exercise program for patients with haematological malignancies after bone marrow transplantation. (1996) (209)
Hematologic effects of recombinant human granulocyte colony-stimulating factor in patients with malignancy. (1989) (205)
Pharmacokinetics of recombinant interleukin 2 in humans. (1990) (205)
Participation of the cytokines interleukin 6, tumor necrosis factor-alpha, and interleukin 1-beta secreted by acute myelogenous leukemia blasts in autocrine and paracrine leukemia growth control. (1989) (199)
Effects of recombinant human interleukin-3 in patients with normal hematopoiesis and in patients with bone marrow failure (1990) (196)
Granulocyte-macrophage colony-stimulating factor induces cytokine secretion by human polymorphonuclear leukocytes. (1989) (195)
BCL-2/JH rearrangements in circulating B cells of healthy blood donors and patients with nonmalignant diseases. (1996) (188)
IL‐10 induces DNA binding activity of three STAT proteins (Stat1, Stat3, and Stat5) and their distinct combinatorial assembly in the promoters of selected genes (1996) (187)
Tumor necrosis factor (TNF)-alpha but not TNF-beta induces secretion of colony stimulating factor for macrophages (CSF-1) by human monocytes. (1987) (182)
Hematopoietic responses in patients with advanced malignancy treated with recombinant human granulocyte-macrophage colony-stimulating factor. (1989) (173)
Multimodality treatment including early high-dose chemotherapy with peripheral blood stem cell transplantation in limited-disease small cell lung cancer. (1998) (173)
Biological activities of a human pluripotent hemopoietic colony stimulating factor on normal and leukemic cells (1985) (169)
Acute lymphoblastic leukemia in adults. (1985) (168)
Granulocyte/macrophage colony-stimulating factor induces interleukin 1 production by human polymorphonuclear neutrophils. (1988) (165)
Correlation between physical performance and fatigue in cancer patients. (1997) (163)
Erythropoietin for the treatment of anemia of malignancy associated with neoplastic bone marrow infiltration. (1990) (157)
Treatment decision-making for older patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: problems and approaches. (2006) (148)
Treatment of acute lymphoblastic leukemia in adults: results of the L-10 and L-10M protocols. (1983) (147)
Positively selected autologous blood CD34+ cells and unseparated peripheral blood progenitor cells mediate identical hematopoietic engraftment after high-dose VP16, ifosfamide, carboplatin, and epirubicin (1994) (146)
Purification of human interleukin 2 to apparent homogeneity and its molecular heterogeneity (1982) (145)
Expression of bcl-2 in Burkitt's lymphoma cell lines: induction by latent Epstein-Barr virus genes. (1992) (143)
Interleukin 1 stimulates T lymphocytes to produce granulocyte-monocyte colony-stimulating factor. (1988) (142)
Plasticity of bone marrow-derived stem cells. (2000) (142)
Interleukin 2 regulates the expression of Tac antigen on peripheral blood T lymphocytes (1984) (142)
Phase I clinical trial of 13-cis-retinoic acid in myelodysplastic syndromes. (1983) (137)
Stimulation of immunoglobulin secretion in human B lymphocytes as a direct effect of high concentrations of IL 2. (1984) (134)
Immunotherapy of metastatic malignant melanoma by a vaccine consisting of autologous interleukin 2-transfected cancer cells: outcome of a phase I study. (1999) (129)
Randomized study of 13-cis retinoic acid v placebo in the myelodysplastic disorders. (1988) (128)
Aerobic exercise in the rehabilitation of cancer patients after high dose chemotherapy and autologous peripheral stem cell transplantation. (1998) (123)
The epitope recognized by rituximab. (2006) (121)
Adoptive immunotherapy for relapsed multiple myeloma after allogeneic bone marrow transplantation (BMT): evidence for a graft-versus-myeloma effect (1997) (120)
Specific translocations characterize Burkitt's-like lymphoma of homosexual men with the acquired immunodeficiency syndrome. (1983) (119)
Leukotriene B4 transcriptionally activates interleukin‐6 expression involving NK‐xB and NF‐IL6 (1992) (114)
Ex vivo expansion of enriched peripheral blood CD34+ progenitor cells by stem cell factor, interleukin-1 beta (IL-1 beta), IL-6, IL-3, interferon-gamma, and erythropoietin. (1993) (110)
Morphological classification, response to therapy, and survival in 263 adult patients with acute nonlymphoblastic leukemia. (1980) (109)
Immunologic effects of interleukin 2 in primary immunodeficiency diseases. (1983) (108)
Interleukin-4 induces secretion of CSF for granulocytes and CSF for macrophages by peripheral blood monocytes. (1989) (106)
Homing of intravenously and intralymphatically injected human dendritic cells generated in vitro from CD34+ hematopoietic progenitor cells (1999) (105)
N-ras gene point mutations in childhood acute lymphocytic leukemia correlate with a poor prognosis. (1990) (105)
Defective interleukin 2 production in patients after bone marrow transplantation and in vitro restoration of defective T lymphocyte proliferation by highly purified interleukin 2. (1984) (104)
Delineation of the dendritic cell lineage by generating large numbers of Birbeck granule-positive Langerhans cells from human peripheral blood progenitor cells in vitro. (1995) (103)
Characterization of malignant lymphomas in leukemic phase by multiple differentiation markers of mononuclear cells. Correlations with clinical features and conventional morphology. (1977) (100)
Effect of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndrome with excess blasts. (1989) (98)
Maintenance of transplantation potential in ex vivo expanded CD34(+)- selected human peripheral blood progenitor cells (1994) (94)
Phase II trial of intravenous endotoxin in patients with colorectal and non-small cell lung cancer. (1996) (93)
GM-CSF in a double-blind randomized, placebo controlled trial in therapy of adult patients with de novo acute myeloid leukemia (AML). (1995) (88)
High-Level Secretion of Tumor Necrosis Factor-alpha Contributes to Hematopoietic Failure in Hairy Cell Leukemia (1989) (86)
Phase I and II clinical and pharmacological study of 4-demethoxydaunorubicin (idarubicin) in adult patients with acute leukemia. (1985) (86)
Interleukin-10 increases Bcl-2 expression and survival in primary human CD34+ hematopoietic progenitor cells. (1996) (86)
Maintenance of transplantation potential in ex vivo expanded CD34(+)-selected human peripheral blood progenitor cells. (1994) (85)
Expression of cytokine genes, cytokine receptor genes, and transcription factors in cultured Hodgkin and Reed-Sternberg cells. (1992) (85)
Production of macrophage‐, granulocyte‐, granulocyte‐macrophage‐ and multi‐colony‐stimulating factor by peripheral blood cells (1989) (84)
Vascular endothelial growth factor (VEGF) mRNA expression in human tumor models of different histologies. (1995) (82)
Granulocyte-macrophage colony-stimulating factor (CSF) and multilineage CSF recruit human monocytes to express granulocyte CSF. (1989) (79)
Lymphoblastic neoplasia in a homosexual patient with Kaposi's sarcoma. (1983) (77)
In vitro differentiation of CD34+ hematopoietic progenitor cells toward distinct dendritic cell subsets of the birbeck granule and MIIC-positive Langerhans cell and the interdigitating dendritic cell type. (1996) (76)
Peripheral blood progenitor cells mobilized by chemotherapy plus granulocyte‐colony stimulating factor accelerate both neutrophil and platelet recovery after high‐dose VP16, ifosfamide and cisplatin (1993) (75)
Interleukin-4 inhibits growth of multiple myelomas by suppressing interleukin-6 expression. (1991) (75)
A phase‐I clinical study of autologous tumor cells plus interleukin‐2‐gene‐transfected allogeneic fibroblasts as a vaccine in patients with cancer (1997) (74)
Sequential administration of interleukin-3 and granulocyte-macrophage colony-stimulating factor following standard-dose combination chemotherapy with etoposide, ifosfamide, and cisplatin. (1992) (74)
Biologic effects of recombinant human interleukin-3 in vivo. (1991) (72)
Production of and in vitro response to interleukin 2 in the acquired immunodeficiency syndrome. (1985) (72)
The JAK-STAT pathway: signal transduction involved in proliferation, differentiation and transformation. (1998) (71)
Regulatory role of a monomorphic determinant of HLA Class I antigens in T cell proliferation. (1985) (69)
Pluripoietin alpha: a second human hematopoietic colony-stimulating factor produced by the human bladder carcinoma cell line 5637. (1986) (69)
Acute nonlymphoblastic leukemia. Prognostic factors in adults with long‐term follow‐up (1982) (69)
Mobilization of peripheral blood progenitor cells for allogeneic transplantation: efficacy and toxicity of a high-dose rhG-CSF regimen. (1996) (68)
Phase III randomized study of two fluorouracil combinations with either interferon alfa-2a or leucovorin for advanced colorectal cancer. Corfu-A Study Group. (1995) (67)
Effect of granulocyte-macrophage colony-stimulating factor on neutropenia and related morbidity induced by myelotoxic chemotherapy. (1990) (65)
Evidence for distinct lymphocytic and monocytic populations in a patient with terminal transferase--positive acute leukemia (1978) (64)
Six, Not Eight Cycles of Bi-Weekly CHOP with Rituximab (R-CHOP-14) Is the Preferred Treatment for Elderly Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Results of the RICOVER-60 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). (2005) (64)
Functional consequences of monocyte IL-2 receptor expression. Induction of IL-1 beta secretion by IFN gamma and IL-2. (1989) (62)
Lymphoblastic lymphoma in adults. (1986) (62)
Cytokine‐stimulation of prostaglandin synthesis from endogenous and exogenous arachidonic acids in polymorphonuclear leukocytes involving activation and new synthesis of cyclooxygenase (1990) (61)
Generation of nonspecific murine cytotoxic T cells in vitro by purified human interleukin 2. (1984) (61)
OKT8 antibody inhibits OKT3-induced IL 2 production and proliferation in OKT8+ cells. (1983) (60)
Amsacrine with high-dose cytarabine is highly effective therapy for refractory and relapsed acute lymphoblastic leukemia in adults. (1988) (60)
Expansion of cyclophosphamide-resistant cytotoxic precursors in vitro and in vivo by purified human interleukin 2. (1983) (59)
Effect of interleukin 3 on cytosine arabinoside-mediated cytotoxicity of leukemic myeloblasts. (1990) (59)
The acute monocytic leukemias: multidisciplinary studies in 45 patients. (1980) (58)
Lymphokine activated killer cells (1989) (58)
Systemic infection with Trichosporon cutaneum in a patient with acute leukemia: Report of a case (1981) (57)
CD34+ peripheral blood progenitor cell and monocyte derived dendritic cells: a comparative analysis (1997) (57)
Comparative trial of cytarabine and thioguanine in combination with amsacrine or daunorubicin in patients with untreated acute nonlymphocytic leukemia: results of the L-16M protocol. (1989) (56)
Adhesion and migration are differentially regulated in hematopoietic progenitor cells by cytokines and extracellular matrix. (1997) (55)
Improved biochemical assay for terminal deoxynucleotidyl transferase in human blood cells: Results in 89 adult patients with lymphoid leukemias and malignant lymphomas in leukemic phase (1978) (55)
Leukostasis followed by hemorrhage complicating the initiation of chemotherapy in patients with acute myeloid leukemia and hyperleukocytosis (1999) (54)
Phase I trial of recombinant human tumour necrosis factor α in patients with advanced malignancy (1991) (54)
Human pluripotent hemopoietic colony stimulating factor: activities on human and murine cells. (1986) (53)
Allogeneic transplantation of positively selected peripheral blood CD34+ progenitor cells from matched related donors. (1996) (53)
Primary fibroblasts from human adults as target cells for ex vivo transfection and gene therapy. (1994) (52)
Abnormally high concentrations of beta 2 microglobulin in acquired immunodeficiency syndrome (AIDS) patients. (1983) (52)
High-dose cytosine arabinoside in combination with mitoxantrone for the treatment of refractory acute myeloid and lymphoblastic leukemia. (1987) (51)
CLL B-cell receptors can recognize themselves: alternative epitopes and structural clues for autostimulatory mechanisms in CLL. (2013) (51)
Induction of multiple‐drug resistance during anti‐neoplastic chemotherapy in vitro (1991) (51)
Induction of differentiation in human marrow T cell precursors by the synthetic serum thymic factor, FTS. (1980) (50)
Autologous and allogeneic mixed-lymphocyte responses following thermal injury in man: the immunomodulatory effects of interleukin 1, interleukin 2, and a prostaglandin inhibitor, WY-18251. (1984) (49)
Granulocyte-macrophage colony-stimulating factor and interleukin-3 induce surface expression of interleukin-2 receptor p55-chain and CD4 by human eosinophils. (1990) (49)
Human interleukin 2: molecular biology, physiology and clinical possibilities. (1986) (48)
Mithramycin selectively inhibits collagen-alpha 1(I) gene expression in human fibroblast. (1993) (48)
Differential Kinetics of Primitive Hematopoietic Cells Assayed In Vitro and In Vivo During Serum‐Free Suspension Culture of CD34+ Blood Progenitor Cells (1999) (47)
Interleukin-2 production and response to interleukin-2 by peripheral blood mononuclear cells from patients after bone marrow transplantation: II. Patients receiving soybean lectin-separated and T cell-depleted bone marrow. (1987) (47)
Regulation of gene expression of M-, G-, GM-, and multi-CSF in normal and malignant hematopoietic cells. (1988) (47)
Transforming growth factor‐beta 1 delays formation of granulocyte‐macrophage colony‐forming cells, but spares more primitive progenitors during ex vivo expansion of CD34+ haemopoietic progenitor cells (1997) (46)
Treatment of advanced Hodgkin's disease with chemotherapy and irradiation. Controlled trial of two versus three alternating, potentially non-cross-resistant drug combinations. (1984) (45)
Prognostic significance of terminal deoxynucleotidyl transferase activity in acute nonlymphoblastic leukemia. (1986) (45)
Mechanisms of p53 alteration in acute leukemias. (1994) (45)
Generation of antigen‐presenting cells for soluble protein antigens ex vivo from peripheral blood CD34+ hematopoietic progenitor cells in cancer patients (1996) (45)
Clonal analysis of bcr-abl rearrangement in T lymphocytes from patients with chronic myelogenous leukemia (1992) (44)
Prevalence of N-ras mutations in children with myelodysplastic syndromes and acute myeloid leukemia. (1992) (44)
Incidence of lineage promiscuity in acute myeloblastic leukemia: diagnostic implications of immunoglobulin and T-cell receptor gene rearrangement analysis and immunological phenotyping. (1988) (44)
Imatinib mesylate as a novel treatment option for hypereosinophilic syndrome: two case reports and a comprehensive review of the literature (2005) (44)
Effects of recombinant human interleukin-3 in patients with normal hematopoiesis and in patients with bone marrow failure. (1990) (43)
Allogeneic bone marrow transplantation from unrelated donors using in vivo anti‐T‐cell globulin (2000) (43)
Positively selected autologous blood CD34+ cells and unseparated peripheral blood progenitor cells mediate identical hematopoietic engraftment after high-dose VP16, ifosfamide, carboplatin, and epirubicin. (1994) (43)
Effect of long-term treatment with recombinant human interleukin-3 in patients with myelodysplastic syndromes. (1993) (42)
Downregulation of the proinflammatory cytokine response to endotoxin by pretreatment with the nontoxic lipid A analog SDZ MRL 953 in cancer patients. (1997) (41)
Philadelphia chromosome and terminal transferase-positive acute leukemia: similarity of terminal phase of chronic myelogenous leukemia and de novo acute presentation. (1983) (41)
Regulation of M-CSF Expression by M-CSF: Role of Protein Kinase C and Transcription Factor NFkB (1991) (40)
Primary therapy of acute promyelocytic leukemia: results of amsacrine- and daunorubicin-based therapy (1984) (40)
Prognosis of older patients with acute myeloid leukemia receiving either induction or noncurative treatment: a single-center retrospective study (2003) (40)
Clinical Effects of Recombinant Human Interleukin‐3 (1991) (40)
Recombinant human granulocyte‐macrophage colony‐stimulating factor induces secretion of autoinhibitory monokines by U‐937 cells (1988) (40)
Immunostimulatory cytokines in somatic cells and gene therapy of cancer. (1997) (39)
Expression of leukemia inhibitory factor is regulated in human mesenchymal cells. (1991) (38)
Interleukin 2-dependent natural killer (NK) cell lines from patients with primary T cell immunodeficiencies. (1983) (38)
Interleukin-6 (IL-6) is an intermediate in IL-1-induced proliferation of leukemic human megakaryoblasts. (1990) (37)
T-cell activation defect in common variable immunodeficiency: restoration by phorbol myristate acetate (PMA) or allogeneic macrophages. (1987) (37)
Expression of interleukin 10 in B lymphocytes of different origin. (1993) (37)
Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 100 consecutive patients with limited- and extensive-disease small-cell lung cancer. (1997) (37)
Diagnostic and prognostic significance of the CFU-c assay in acute nonlymphoblastic leukemia. (1981) (37)
B‐cell receptor epitope recognition correlates with the clinical course of chronic lymphocytic leukemia (2011) (36)
High-level secretion of tumor necrosis factor-alpha contributes to hematopoietic failure in hairy cell leukemia. (1989) (36)
Hematopoietic Growth Factors in Clinical Applications (1990) (36)
Induction of tumor-specific cytotoxic T lymphocytes by immunization with autologous tumor cells and interleukin-2 gene transfected fibroblasts (1997) (36)
Identification of their epitope reveals the structural basis for the mechanism of action of the immunosuppressive antibodies basiliximab and daclizumab. (2007) (35)
Role of colony-stimulating factors in the biology of acute myelogenous leukemia. (1989) (35)
Blood progenitor cell (BPC) mobilization studied in multiple myeloma, solid tumor and non-Hodgkin’s lymphoma patients after combination chemotherapy and G-CSF (1997) (34)
Treatment of immunodeficiency with interleukin-2: initial exploration. (1984) (34)
Clinical experience with the combined use of recombinant interleukin‐2 (IL2) and interferon alfa‐2a (IFNα) in metastatic melanoma (1991) (34)
Influence of recombinant human granulocyte colony-stimulating factor (filgrastim) on hematopoietic recovery and outcome following allogeneic bone marrow transplantation (BMT) from volunteer unrelated donors (1999) (34)
Interleukin-6 and interleukin-11 act synergistically with thrombopoietin and stem cell factor to modulate ex vivo expansion of human CD41+ and CD61+ megakaryocytic cells. (2000) (34)
A switch toward demethylation is associated with the expression of myeloperoxidase in acute myeloblastic and promyelocytic leukemias. (1992) (33)
Phase I study to the immunotherapy of metastatic malignant melanoma by a cancer vaccine consisting of autologous cancer cells transfected with the human IL-2 gene. (1996) (33)
Evidence for distinct lymphocytic and monocytic populations in a patient with terminal transferase--positive acute leukemia. (1978) (33)
The microenvironment differentially impairs passive and active immunotherapy in chronic lymphocytic leukaemia – CXCR4 antagonists as potential adjuvants for monoclonal antibodies (2010) (33)
Allogeneic bone marrow transplantation from unrelated donors using in vivo anti-T-cell globulin (2000) (32)
Human interleukin 2: biochemistry, physiology, and possible pathogenetic role in immunodeficiency syndromes. (1985) (32)
Hematopoietic growth factors in bone marrow transplantation. (1990) (31)
Busulfan/cyclophosphamide in volunteer unrelated donor (VUD) BMT: excellent feasibility and low incidence of treatment-related toxicity (1997) (31)
Serum-free ex vivo expansion of CD34(+) hematopoietic progenitor cells. (1998) (31)
Efficient serum-free retroviral gene transfer into primitive human hematopoietic progenitor cells by a defined, high-titer, nonconcentrated vector-containing medium. (1998) (30)
Developmental regulation of myeloid gene expression and demethylation during ex vivo culture of peripheral blood progenitor cells. (1996) (30)
Interleukin-2 correction of defectivein vitro T-cell mitogenesis in patients with common varied immunodeficiency (1984) (30)
The suppressive effects of recombinant human tumor necrosis factor-alpha on normal and malignant myelopoiesis: synergism with interferon-gamma. (1988) (30)
Phase I trial of recombinant human tumour necrosis factor alpha in patients with advanced malignancy. (1991) (30)
Treatment of stages I and II Hodgkin's disease with three different therapeutic modalities. (1986) (30)
Serum levels of circulating ICAM-1 are increased in Hodgkin's disease. (1993) (30)
Elevated circulating levels of tumor necrosis factor predict unresponsiveness to treatment with interferon alfa-2b in chronic myelogenous leukemia. (1992) (29)
Cytokine and chemokine production by CD34+ haemopoietic progenitor cells: detection in single cells (1997) (29)
Interleukin-3: structure and function. (1993) (29)
Functional expression of c-kit by acute myelogenous leukemia blasts is enhanced by tumor necrosis factor-alpha through posttranscriptional mRNA stabilization by a labile protein. (1992) (29)
Mechanisms of differential regulation of interleukin‐6 mRNA accumulation by tumor necrosis factor alpha and lymphotoxin during monocytic differentiation (1990) (28)
Interleukin-2 and interferon-gamma recruit different subsets of human peripheral blood monocytes to secrete interleukin-1 beta and tumour necrosis factor-alpha. (1989) (28)
Efficient gene transfer in primitive CD34+/CD38lo human bone marrow cells reselected after long-term exposure to GALV-pseudotyped retroviral vector. (1997) (27)
Current status of treatment of acute leukemia in adults: an overview of the Memorial experience and review of literature. (1986) (27)
Interleukin-1 beta (IL-1 beta) expression in human blood mononuclear phagocytes is differentially regulated by granulocyte-macrophage colony- stimulating factor (GM-CSF), M-CSF, and IL-3 (1992) (27)
In vivo effects of granulocyte-macrophage colony-stimulating factor and interleukin-3 on clonal and non-clonal cell populations in patients with clonal hematopoietic disorders. (1991) (27)
Heterogeneity of cell lineages in L3 leukemias. (1980) (25)
Human B cell-inducing factor(s) for production of IgM, IgG and IgA: independence from IL 2. (1984) (25)
Regulation of gene expression of macrophage‐colony stimulating factor in human fibroblasts by the acute phase response mediators interleukin (IL)‐1β, tumor necrosis factor‐α and IL‐6 (1991) (25)
The immunotherapy of human cancer with interleukin 2: present status and future directions. (1991) (25)
Synthesis of granulocyte colony-stimulating factor and its requirement for terminal divisions in chronic myelogenous leukemia (1990) (25)
A phase-II study of low-dose cyclophosphamide and recombinant human interleukin-2 in metastatic renal cell carcinoma and malignant melanoma (2004) (25)
Hematopoietic Stem Cells: Biology and Therapeutic Applications (1995) (25)
Treatment of acute leukemia in relapse with 4'(9-acridinylamino) methanesulfon-m-anisidide (AMSA) in combination with cytosine arabinoside and thioguanine. (1981) (24)
Purification and some properties of a soluble DNA-dependent RNA polymerase from nuclei of human placenta. (1969) (24)
Use of high-dose etoposide/ifosfamide/carboplatin/epirubicin and peripheral blood progenitor cell transplantation in limited-disease small cell lung cancer. (1995) (24)
Endotoxin (Salmonella abortus equi) in cancer patients. Clinical and immunological findings. (1995) (24)
Leukemia cell phenotype and prognosis: an analysis of 519 adults with acute leukemia. (1982) (24)
Effect of granulocyte-macrophage colony-stimulating factor on neutropenia and related morbidity induced by myelotoxic chemotherapy. (1990) (24)
High concentrations of the interleukin-1 receptor antagonist in serum of patients with Hodgkin's disease (1992) (24)
Raf-1 is a necessary component of the mitogenic response of the human megakaryoblastic leukemia cell line MO7 to human stem cell factor, granulocyte-macrophage colony-stimulating factor, interleukin 3, and interleukin 9. (1994) (24)
[Tumor necrosis factor]. (1989) (23)
New developments in hematopoietic stem cell expansion (1998) (22)
Regulation of M-CSF expression by M-CSF: role of protein kinase C and transcription factor NF kappa B. (1991) (22)
AEROBIC EXERCISE IN THE REHABILITATION OF CANCER PATIENTS 1578 (1997) (22)
Aspergillus peritonitis complicating perforated appendicitis in adult acute leukemia (1982) (22)
Interferon‐gamma interrupts autocrine growth mediated by endogenous interleukin‐6 in renal‐cell carcinoma (1991) (21)
The significance of serum levels of soluble 60kDa receptors for tumor necrosis factor in patients with Hodgkin's disease. (1993) (21)
Production and response to interleukin 2 in vitro and in vivo after bone marrow transplantation in mice. (1985) (21)
Yeast-expressed granulocyte-macrophage colony-stimulating factor in cancer patients: a phase ib clinical study. (1988) (21)
Sodium azide enhancement of interleukin-2 production. (1983) (21)
The transjugular stent implantation for the treatment of malignant portal and hepatic vein obstruction in cancer patients. (1997) (20)
Phase I study to the immunotherapy of metastatic malignant melanoma by a cancer vaccine consisting of autologous cancer cells transfected with the human IL-2 gene (1997) (20)
In vivo biology and therapeutic potential of hematopoietic growth factors and circulating progenitor cells. (1992) (20)
Paracrine stimulation of keratinocytes in vitro and continuous delivery of epidermal growth factor to wounds in vivo by genetically modified fibroblasts transfected with a novel chimeric construct. (1997) (20)
Differential regulation of interleukin‐6 expression in human fibroblasts by tumor necrosis factor‐α and lymphotoxin (1990) (19)
Production and regulation of interleukin-2 in human lymphoblastic leukemias studied with T-cell monoclonal antibodies (1983) (19)
A European perspective on haematopoietic growth factors in haemato-oncology: report of an expert meeting of the EORTC. (1997) (19)
B cells from a patient with chronic lymphocytic leukemia bind to sheep erythrocytes: an immunological analysis. (1980) (19)
In vivo recruitment of GM-CSF-response myelopoietic progenitor cells by interleukin-3 in aplastic anemia. (1990) (19)
Purification to apparent homogeneity and biochemical characterization of human pluripotent hematopoietic colony-stimulating factor. (1985) (18)
Recognition by human Vγ9/Vδ2 T cells of melanoma cells upon fusion with Daudi cells (1996) (18)
Chemotherapy of Hodgkin’s lymphoma with alternating cycles of COPP (cyclophosphamide, vincristin, procarbazine, prednisone) and ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine). Results of the HD1 and HD3 trials of the German Hodgkin Study Group (1989) (18)
Synergy of interleukin 3 and tumor necrosis factor alpha in stimulating clonal growth of acute myelogenous leukemia blasts is the result of induction of secondary hematopoietic cytokines by tumor necrosis factor alpha. (1992) (18)
Current Status of Treatment of Acute Leukemia in Adults: An Overview (1984) (18)
Fibrinogen gamma-chain mRNA is not detected in human megakaryocytes. (1991) (18)
Leukemic colony-forming cells in acute myeloblastic leukemia: maturation hierarchy and growth conditions. (1987) (18)
Standard- and high-dose etoposide, ifosfamide, carboplatin, and epirubicin in 107 patients with non-small-cell lung cancer: a mature follow-up report. (1999) (18)
Combination of interleukin-2 and interferon-alpha in renal cell carcinoma and malignant melanoma: a phase II clinical trial. (1992) (17)
Lymphokine-activated killer cells are generated before classical cytotoxic T lymphocytes after bone marrow transplantation in mice. (1985) (17)
Activation of NF-kappa B by interleukin 2 in human blood monocytes. (1992) (17)
Defective T-cell response to PHA and mitogenic monoclonal antibodies in male homosexuals with acquired immunodeficiency syndrome and itsin vitro correction by interleukin 2 (1983) (16)
Clinical and immunomodulatory effects of repetitive 2-day cycles of high-dose continuous infusion IL-2. (1997) (16)
Minimal residual disease: detection, clinical relevance, and treatment strategies. (1996) (16)
Cytokine therapy with gene-transfected cells: single injection of irradiated granulocyte-macrophage colony-stimulating factor-transduced cells accelerates hematopoietic recovery after cytotoxic chemotherapy in mice. (1994) (16)
Burkitt-like mutations in the c-myc gene locus in prolymphocytic leukemia. (1994) (16)
Production and regulation of interleukin-2 in human lymphoblastic leukemias studied with T-cell monoclonal antibodies. (1983) (16)
Cytofluorometric detection of chronic myelocytic leukemia supervening in a patient with chronic lymphocytic leukemia. (1986) (16)
Human interleukin 2: physiology, biochemistry, and pathophysiology in lymphoblastic leukemias and immunodeficiency syndromes. (1983) (16)
BCL-2 induction is part of the strategy of Epstein-Barr virus. (1994) (16)
Clonal analysis of bcr-abl rearrangement in T lymphocytes from patients with chronic myelogenous leukemia. (1992) (16)
N-RAS gene activation in acute myeloid leukemia: association with expression of interleukin-6. (1993) (15)
HTLV-I-associated adult T cell leukemia/lymphoma in two patients from Bucharest, Romania. (1996) (15)
Sequential Marrow Culture Studies and Terminal Deoxynucleotidyl Transferase Activities in Myelodysplastic Syndromes (1979) (15)
Biological and clinical advances in stem cell expansion. (1996) (15)
Cytosine methylation changes during normal hematopoiesis and in acute myeloid leukemia. (1997) (15)
Supportive care in hematological malignancies: hematopoietic growth factors, infections, transfusion therapy. (1999) (15)
Expression of functional receptors for interleukin‐6 by human polymorphonuclear, leukocytes Downregulation by granulocyte‐macrophage colony‐stimulating factor (1991) (15)
Interleukin-8 serum levels for early detection of infectious episodes in neutropenic patients. (1995) (15)
Interleukin-1 beta (IL-1 beta) expression in human blood mononuclear phagocytes is differentially regulated by granulocyte-macrophage colony-stimulating factor (GM-CSF), M-CSF, and IL-3. (1992) (15)
Systematic evaluation of chimeric marker genes on dicistronic transcription units for regulated expression of transgenes in vitro and in vivo. (1996) (15)
Induction of monocytic differentiation and modulation of the expression of c-fos, c-fms and c-myc protooncogenes in human monoblasts by cytokines and phorbolester (1990) (15)
Correlation analyses between CD34+ cells and clonogenic progenitors mobilized into the peripheral blood by IL‐3 + GM‐CSF following polychemotherapy in cancer patients (1992) (15)
160 years of multiple myeloma: progress and challenges. (2006) (15)
Interleukin 2: a review. (1985) (14)
Processing of tumor tissues for vaccination with autologous tumor cells. (1997) (14)
Supportive care in hematologic malignancies (1998) (14)
The human lysozyme gene undergoes stepwise demethylation during phagocyte maturation (1997) (13)
Combination of cytokines: current status and future prospects (1991) (13)
Interleukin‐4 regulates mRNA accumulation of macrophage‐colony stimulating factor by fibroblasts: synergism with interleukin‐1β (1990) (13)
In vivo administration of recombinant human interleukin-3 elicits an acute phase response involving endogenous synthesis of interleukin-6. (1991) (13)
Early-onset secondary malignancies after high-dose chemotherapy and autologous hematopoietic stem cell transplantation (1997) (13)
Analysis of multiple cell markers in acute leukemia complicating Hodgkin's disease (1980) (13)
Human interleukin 2 gene is located on chromosome 4. (1984) (13)
Standard- and high-dose etoposide, ifosfamide, carboplatin, and epirubicin in 100 patients with small-cell lung cancer: a mature follow-up report. (1999) (13)
Primary therapy of acute promyelocytic leukemia: results of amsacrine- and daunorubicin-based therapy. (1984) (13)
The prognostic significance of terminal deoxynucleotidyl transferase (TDT) in patients with leukemias and malignant lymphomas. (1982) (13)
Phenotypic evaluation of chronic myeloid leukemia. (1981) (12)
Lysis of spontaneous murine breast tumors by human interleukin 2-stimulated syngeneic T-lymphocytes. (1985) (12)
Subpopulations of human T lymphocytes VI. Analysis of cell markers in acute lymphoblastic leukemia with special reference to Fc receptor expression on E‐rosette‐forming blasts (1980) (12)
Umbilical cord blood: an alternative to the transplantation of bone marrow stem cells. (1996) (12)
Meeting summary: European Workshop on Stem Cells, European Centre for the Validation of Biomedical Testing Methods, Institute for Health and Consumer Protection, Joint Research Centre, Ispra, Italy, November 21-23, 2001. (2002) (12)
Expression of the Fas antigen on primary human leukemia cells (2005) (12)
Isolation and purification of DNA-dependent RNA polymerase from nuclei of human placenta. (Nucleoside triphosphate: ribonucleic acid nucleotidyl transferase, e.c.2.7.7.6.). (1968) (12)
Favourable outcomes of poor prognosis diffuse large B‐cell lymphoma patients treated with dose‐dense Rituximab, high‐dose Methotrexate and six cycles of CHOP‐14 compared to first‐line autologous transplantation (2017) (12)
Translocation t(8;13) in a patient with T cell lymphoma and features of a myeloproliferative syndrome. (1995) (12)
Non-Intensive AML/MDS Treatment with Low-Dose Decitabine Prior to Reduced-Intensity Conditioning (RIC) and Allogeneic Blood Stem Cell Transplantation of Older Patients. (2006) (12)
Treatment of acute nonlymphocytic leukemia in adults: Response to 2,2‐anhydro‐1‐B‐D‐Arabinofuranosyl‐5‐fluorocytosine and thioguanine on the L‐12 protocol (1981) (11)
G-CSF and M-CSF: From molecular biology to clinical application (1990) (11)
Peripheral blood stem cells: In vivo biology and therapeutic potential (1994) (11)
Hematopoietins in combination with 1-beta-D-arabinofuranosylcytosine: a possible strategy for improved treatment of myeloid disorders. (1992) (11)
13-cis-Retinoic acid does not increase the true remission rate and the duration of true remission (induced by cytotoxic chemotherapy) in patients with chronic phase chronic myelogenous leukemia. (1985) (11)
Induction of c-jun expression in the myeloid leukemia cell line KG-1 by 1-beta-D-arabinofuranosylcytosine. (1991) (11)
Treatment of refractory adult lymphoblastic leukemia (ALL) with 4'(9-acridinylamino) methanesulfon-M-anisidide (AMSA). (1982) (11)
Monokines: stimulatory and inhibitory regulator molecules of myelopoiesis in vitro. (1988) (11)
Stimulation of granulopoiesis in patients with malignancy by recombinant human granulocyte-macrophage colony-stimulating factor: assessment of two routes of administration. (1990) (10)
Serum Cytokine Levels in Cancer Patients Treated with Different Schedules of Ultra‐Low-Dose Interleukin‐2 (1994) (10)
Interleukin-3 and its receptor. (1995) (10)
Immunomodulatory effects of ultra-low-dose interleukin-2 in cancer patients: a phase-IB study (1993) (10)
Successful treatment of disseminated central nervous aspergillosis in a patient with acute myeloblastic leukemia. (1997) (10)
Polypeptides controlling hematopoietic blood cell development and activation (1989) (10)
Splenic hematopoiesis following GM-CSF therapy in a patient with hairy cell leukemia. (1990) (10)
Polypeptides controlling hematopoietic cell development and activation (1989) (10)
Modulation of vindesine and doxorubicin resistance in multidrug-resistant pleural mesothelioma cells by tumor necrosis factor-alpha. (1995) (10)
Cytokine gene transfer in cancer therapy (1998) (10)
Natural inhibitors of T-cell activation in Hodgkin's disease (1991) (9)
Clinical significance of TdT, cell surface markers and CFU-C in 297 patients with hematopoietic neoplasias. (1979) (9)
Ultrastructural demonstration of terminal deoxynucleotidyl transferase (TdT) (1981) (9)
Systemic hematological effects of granulocyte colony-stimulating factor produced by irradiated gene-transfected fibroblasts. (1996) (9)
Development of image analysis software for quantification of viable cells in microchips (2018) (9)
Screening for expression of cytokines with hematopoietic growth factor activity by permanent human B-cell lines. (1991) (9)
Cloning and sequence analysis of the immediate promoter region and cDNA of porcine granulocyte colony-stimulating factor. (1997) (9)
A phase I trial of intraperitoneal recombinant interleukin 2 in patients with ovarian carcinoma (1988) (9)
Autologous stem cell transplant for poor prognosis lymphoma (1985) (9)
Minimal peripheral blood cells carrying clonal markers of B cell disorders: evidence for monoclonality of circulating lymphocytes in patients with multiple myeloma. (1989) (9)
Clinical use of recombinant human hematopoietic growth factors (GM-CSF, IL-3, EPO) in patients with myelodysplastic syndrome. (1991) (9)
Acute myelomonocytic leukemia secondary to synchronous carcinomas of the breast and lung, and to metachronous renal cell carcinoma (1997) (8)
Minimal residual disease in autologous hematopoietic harvests from breast cancer patients. (1998) (8)
Concise manual of hematology and oncology (2008) (8)
Hematopoietins: biology, pathophysiology, and potential as therapeutic agents. (1991) (8)
Cytoprotective function of keratinocyte growth factor in tumour therapy‐induced tissue damage (2002) (8)
Rescue of anti-influenza A virus cytotoxic T-lymphocyte responses in chemotherapy-suppressed mice (1984) (8)
T-cell growth factor (interleukin 2) control of T-lymphocyte proliferation: possible involvement in leukemogenesis. (1981) (8)
Secretion of granulocyte‐macrophage colony‐stimulating factor by human blood monocytes is stimulated by engagement of Fcγ receptors type I by solid‐phase immunoglobulins requiring high‐affinity Fc‐Fcγ receptor type I interactions (1992) (8)
Constitutive expression of hematopoietic growth factor genes by acute myeloblastic leukemia cells. (1988) (8)
NT-pro-BNP: not the prognostic all-rounder in elderly patients undergoing allogeneic stem cell transplantation (2012) (7)
The coexistence of acute myeloblastic leukemia and diffuse histiocytic lymphoma in the same patient as demonstrated by multiparameter analysis. (1979) (7)
Relationship of Auer rods and chromosome findings to outcome in eighty-nine adults with acute nonlymphoblastic leukemia. (1985) (7)
Retrospective analysis of ras gene activation in myeloid leukemic cells. (1990) (7)
Hematopoietic stem cell transplantation: more than just hematopoietic? (2004) (7)
The use of hematopoietic growth factors for high-dose chemotherapy and peripheral blood progenitor cell transplantation. (1994) (7)
Haematopoietic growth factors and peripheral blood stem cells as supportive agents in dose intensification. (1993) (7)
Hematopoietic cell proliferation and differentiation (1996) (7)
Prognostic significance of receptors for the third component of complement an heavy chain phenotype in diffuse B-cell lymphomas. (1983) (7)
Poor prognosis of prethymic phenotype acute lymphoblastic leukemia (pre-T-ALL). (1994) (6)
Application of basic science to hematopoiesis and treatment of disease. 15th Bristol-Myers Squibb Symposium on Cancer Research held at the Fred Hutchinson Cancer Research Center, Seattle, November 4-5, 1991. (1992) (6)
Neo-adjuvant high-dose chemotherapy with autologous peripheral blood stem cell transplantation for inoperable relapse of nuchal liposarcoma resistant to standard-dose chemotherapy. (1996) (6)
Synergistic effect of recombinant human leukemia inhibitory factor (LIF) and 1-beta-D-arabinofuranosylcytosine (Ara-C) on proto-oncogene expression and induction of differentiation in human U 937 cells. (1990) (6)
Hemopoietins in Clinical Oncology (1991) (6)
Role of hematopoietic growth factor combinations in experimental and clinical oncology. (1992) (6)
Hematopoietic cytokines: from biology and pathophysiology to clinical application. (1993) (6)
High-dose chemotherapy with autologous peripheral blood stem cell transplantation for metastatic gastric leiomyosarcoma (1997) (6)
Cytokines in the pathogenesis and management of non-Hodgkin's lymphomas. (1991) (6)
Modulation of cytotoxicity and differentiation-inducing potential of arabinofuranosylcytosine in myeloid leukemia cells by hematopoietic cytokines. (1993) (6)
Lymphohaematopoietic Growth Factors in Cancer Therapy (2011) (6)
Cost-effective fabrication of photopolymer molds with multi-level microstructures for PDMS microfluidic device manufacture (2020) (6)
Expression of the c-fes proto-oncogene in granulocyte-macrophage colony-stimulating factor-dependent acute myelogenous leukemia cells grown autonomously. (1991) (5)
The significance of splenomegaly in 101 adults with acute lymphoblastic leukemia (ALL) at presentation and during remission. (1981) (5)
Correlation of biochemical and immunological markers with conventional morphology and clinical features in 120 patients with malignant lymphomas. (1979) (5)
Interleukin 2 and interferon alpha-2a do not improve anti-tumour activity of 5-fluorouracil in advanced colorectal cancer. (1996) (5)
Drug resistance of secondary acute myeloid leukemia with megakaryoblastic features and p190 BCR-ABL rearrangement. (1998) (5)
A micromethod for determination of terminal deoxynucleotidyl transferase (TdT) in the diagnostic evaluation of acute leukemias (2004) (5)
The management of primary mediastinal B-cell lymphoma with sclerosis. (1994) (5)
NTS influence on transgene expression from mono- and bicistronic plasmid vectors after lipofection in a human fibroblast cell line (1997) (5)
Detection of allele‐specific expression of N‐RAS oncogenes in human leukaemia cells (1992) (5)
Leukocytoclastic vasculitis and long-term remission in a patient with secondary AML and post-remission treatment with low-dose interleukin-2 (1995) (5)
Cell marker analysis in hematopoietic neoplasias. (1978) (5)
Natural inhibitors of T-cell activation in Hodgkin's disease. (1991) (5)
Apparent decrease and elimination of BCR/ABL mRNA-expressing residual cells in patients with chronic myelogenous leukemia after allogeneic bone marrow transplantation (1991) (5)
Clinical Trials with Haematopoietic Growth Factors and Peripheral Blood Stem Cells (1992) (5)
Supportive care in hematologic malignancies: hematopoietic growth factors, infections, transfusion therapy. (2000) (4)
A stochastic model of myeloid cell lineages in hematopoiesis and pathway mutations in acute myeloid leukemia (2018) (4)
Clonal analysis of n-ras gene activation in acute myeloid leukemia. (1993) (4)
Human Interleukin-2 (1984) (4)
Gamma-interferon interrupts growth stimulation in chronic myelogenous leukemia established by endogenous granulocyte colony-stimulating factor. (1990) (4)
Guidelines for the design and implementation of clinical studies in somatic cell therapy and gene therapy (1995) (4)
Haematopoietic growth factors in clinical medicine. (1994) (4)
Dacarbazine and interferon alpha for stage IV malignant melanoma. (1997) (4)
Monocyte interleukin-1 secretion is regulated by the sequential action of gamma-interferon and interleukin-2 involving monocyte surface expression of interleukin-2 receptors. (1989) (4)
Biological activities of a human pluripotent hemopoietic colony-stimulating factor. (1985) (4)
In Vivo Effects of Interferon-gamma in Chronic Myelogenous Leukemia (1988) (3)
DNA-dependent DNA and RNA polymerases and tRNA-methyl-transferases in human leukemia and differentiating Friend virus leukemia cells. (1974) (3)
Granulocyte–Macrophage Colony-Stimulating Factor in the Therapy of Adults with De Novo Acute Myeloblastic Leukemia: An Update of a Double-Blind Randomized, Placebo-Controlled Trial (1997) (3)
Simultaneous detection of cytokine and immunophenotype at the single cell level by immunoenzymatic double staining (1996) (3)
Regulation of gene expression of macrophage-colony stimulating factor in human fibroblasts by the acute phase response mediators interleukin (IL)-1 beta, tumor necrosis factor-alpha and IL-6. (1991) (3)
Gamma-Interferon Regulates Secretion of G-CSF in Human Monocytes on the Transcriptional Level (1987) (3)
Methods and clinical relevance of terminal deoxynucleotidyl transferase determination in leukemic cells. (1981) (3)
[Current treatment concepts of lung cancer]. (2011) (3)
Medullary histiocytosis following treatment of severe aplastic anemia with recombinant human interleukin-3 in combination with antilymphocyte globulin, cyclosporin A, and methylprednisolone (1991) (3)
Cytotoxicity of TGFα-PE40 and correlation to expression of epidermal growth factor receptor (1995) (3)
Surface Expression of Interleukin-2 Receptors and CD4 Molecules by Human Eosinophils is Induced by GM-CSF and IL-3 (1990) (3)
Patients with secondary acute myelocytic leukemia (AML) receiving "timed" sequential chemotherapy. (1983) (3)
The Role of Maintenance Chemotherapy, Immunotherapy, Induction Dose Reduction in Elderly Patients and Double Induction in the Treatment of Adult Acute Myeloid Leukemia. Four Randomized Studies of the AML Cooperative Group1 (1989) (3)
Erythropoietin prevents chemotherapy-induced anemia: Case report (1990) (3)
Lymphokine factors inducing IgG production in human B-cell line ARH-77 and stimulatory effects of phorbol ester tumor promoter. (1983) (3)
Interferon alfa-2c in chronic myelogenous leukemia (CML): Hematologic, cytogenetic and molecular-genetic response of patients with chronic phase CML previously resistant to therapy with interferon gamma (1990) (3)
Long-term remission after CD34+-selected PBSCT in a patient with advanced intra-abdominal desmoplastic small round-cell tumor (2010) (3)
T- and B-cell responses in patients with malignant pleural effusions. (1981) (3)
Experimental and Clinical Evaluation of Erythropoietin (1990) (3)
Mobilization, purification and ex vivo expansion of human peripheral blood progenitor cells. (1993) (3)
Towards Simulating Carcinogenesis: Modeling and Simulating Carcinogenesis, Hematopoietic Tissue Homeostasis and Leukemogenesis (2016) (3)
In vitro differentiation of CD34+ hematopoietic progenitor cells towards distinct dendritic cell subsets of the MIIC-positive Langerhans cell- and the interdigitating dendritic cell type (1997) (3)
Treatment of patients with anemia of malignancy with recombinant human erythropoietin. (1991) (3)
Response Adapted Assignment of the Number of Chemotherapy Cycles for the Treatment of Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Is Not Justified: Results of the RICOVER-60 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). (2007) (3)
Ultrastructural demonstration of terminal deoxynucleotidyl transferase (TdT). (1981) (3)
Mobilization of peripheral blood progenitor cells by hemopoietic growth factors following standard dose chemotherapy (1992) (3)
Cancer: Modeling evolution and natural selection, the „Mitosis Game“ (2016) (3)
Anti‐tumor activity of a B‐cell receptor‐targeted peptide in a novel disseminated lymphoma xenograft model (2012) (3)
Control of blast cell proliferation and differentiation in acute myelogenous leukemia by soluble polypeptide growth factors. (1990) (3)
Expression of functional receptors for interleukin-6 by human polymorphonuclear leukocytes. Downregulation by granulocyte colony-stimulating factor. (1998) (3)
Recognition by human Vgamma9/Vdelta2 T cells of melanoma cells upon fusion with Daudi cells. (1996) (3)
Present Strategies for Gene Therapy in Cancer (1997) (2)
Allogeneic family-unrelated bone marrow transplantation in acute and chronic myeloid leukemia. (1993) (2)
Hematopoietic cell proliferation and hematopoietic growth factors (1995) (2)
Tumor Immunology and Immunotherapy in Cancer Patients (2016) (2)
Understanding and Controlling Cancer: The Hallmark Concept Revisited – Chance, Evolution and Entropy (2016) (2)
Interleukin-10 and phenomena of tolerance in interleukin-2 therapy. (1996) (2)
Clinical role of colony stimulating factors. (1991) (2)
Interleukin-3 and granulocyte-macrophage colony-stimulating factor in combination: clinical implication. (1992) (2)
Differential regulation of interleukin-6 expression in human fibroblasts by tumor necrosis factor-alpha and lymphotoxin. (1990) (2)
Mechanisms of differential regulation of interleukin-6 mRNA accumulation by tumor necrosis factor alpha and lymphotoxin during monocytic differentiation. (1998) (2)
Plasticity of stem cells. (2001) (2)
T-cell growth factor (Interleukin 2) and terminal transferase activity in human leukemias and lymphoblastic cell lines (1981) (2)
IL-3 plus GM-CSF Induced Recruitment of High Numbers of Peripheral Blood Progenitor Cells Following Standard Dose Chemotherapy (1993) (2)
Modeling and Simulating Carcinogenesis (2018) (2)
The role of erythropoietin in patients with anemia and normal renal function. (1990) (2)
Use of Recombinant Growth Factors after Hematopoietic Cell Transplantation (2007) (2)
Early high-dose chemotherapy and peripheral blood progenitor cell transplantation in limited-disease small-cell lung cancer. Results of a single center phase II study (1997) (2)
Autocrine and Paracrine Stimulation of Growth in Human Acute Myeloid Leukemia (1990) (2)
Regulatory effects of cytokines on myelopoiesis. (1992) (2)
Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 107 consecutive patients with limited- and extensive-stage non-small-cell lung cancer. (1997) (2)
Complete response of metastatic renal cell carcinoma to low-dose interferon-gamma treatment. (1995) (2)
[Coincidence of Hodgkin's disease and epithelioid-cell granulomatosis in liver and spleen]. (1976) (2)
[Immunoscintigraphy of bone marrow in plasmacytoma]. (1995) (2)
In Vitro Effects of Recombinant Human Tumor Necrosis Factor Alpha and Interferon Gamma on Normal and Leukemic Myelopoiesis (1988) (2)
Regulation of T-Cell Proliferation by Interleukin-2 in Male Homosexuals with Acquired Immune Deficiency Syndrome (1984) (2)
Radioimmune Imaging of Bone Marrow in Patients with Plasmocytoma (1995) (2)
Interleukins and Haematopoietic Growth Factors (1990) (2)
Scheduling of ultra low dose interleukin-2 in immunotherapy. (1993) (2)
Antimycotic combination therapy in patients with acute myeloblastic leukemia. (1989) (2)
Is further intensification of treatment warranted in acute nonlymphoblastic leukemia? (1983) (2)
Cytologie and cytochemistry of colony cells in soft agar gel culture from normal and leukemic bone marrow. (1976) (2)
[Haemolytic anaemia and acute renal failure associated with cephalothin and furosemide therapy (author's transl)]. (1976) (1)
Spontanremissionen bei Krebserkrankungen. Internationales Symposium 17.-19. April 1997, Heidelberg (1997) (1)
New Findings on Aclarubicin in the Treatment of Acute Myeloid Leukemia (1990) (1)
The Expression Pattern of Cytokine Genes and Cytokine Receptors by Hodgkin’s Disease-Derived Cell Lines HDLM-2 and KM-H2 Resembles That of Activated T Cells (1992) (1)
blood progenitor cells in vitro of Birbeck granule-positive Langerhans cells from human peripheral Delineation of the dendritic cell lineage by generating large numbers (2011) (1)
Clinical evaluation of hematopoietic growth factors. (1991) (1)
Interleukin I Stimulates T Lymphocytes to Produce Granulocyte-Monocyte Colony-stimulating Factor (1)
Childhood CML in blastic stage: An analysis of cell markers and cell kinetics (1980) (1)
Acute nonlymphocytic leukemia in adults: pathophysiology, status of current therapy, and new approaches. (1987) (1)
Recombinant human interleukin-3 in patients with hematopoietic failure. (1991) (1)
Myeloperoxidase: Gene Demethylation and Expression in Acute Myeloid Leukemias (1992) (1)
Cytokine Interactions in Normal and Malignant Hematopoiesis (1990) (1)
Cytokines and myeloid-specific genes: patterns of expression and possible role in proliferation and differentiation of acute myelogenous leukemia cells. (1993) (1)
Complete response of metastatic renal cell carcinoma to low-dose interferon-γ treatment (1995) (1)
Circadian Variation of α- Amanitine Sensitive RNA-Synthesis in Normal Human Lymphocytes (1976) (1)
MACOP-B Chemotherapy for the treatment of high grade and intermediate grade Non Hodgkin's lymphoma (2005) (1)
Potent Presentation of Soluble Protein Antigens by In Vitro-Generated Dendritic Cells from Peripheral Blood CD34+ Progenitor Cells (1997) (1)
Identification and purification of human erythroid progenitor cells by monoclonal antibody to the transferrin receptor (TÜ 67) (1988) (1)
Unraveling the syndrome of the age-associated diseases : Cancer , Cardiovascular , and Neurological disorders . Common pathways and novel therapeutic strategies (2019) (1)
To overcome pharmacologic and cytokinetic resistance to cytarabine in the treatment of acute myelogenous leukemia by using recombinant interleukin-3? (1991) (1)
RT-PCR for the Diagnosis of Acute Myeloblastic Leukemia with Inv(16) and Detection of Minimal Residual Disease (1998) (1)
Cytokines and hematopoietins: physiology, pathophysiology, and potential as therapeutic agents. (1991) (1)
Cancer Treatment with Cytokines: Concepts and First Clinical Experience (1989) (1)
Chromatin and DNA Methylation Changes of the Human Myeloperoxidase Gene During Myeloid Differentiation (1990) (1)
[Determination of the DNA-dependent RNA polymerase from human leukocytes in a simple cell-free system (author's transl)]. (1973) (1)
Supportive care in hematologic malignancies, including hematopoietic growth factors, transfusions, and infectious complications (1997) (1)
THE ROLE INTERLEUKIN 2 IN THE NEONATE (1984) (1)
Hematopoietins as Adjuvant Therapy in Cancer Patients (1990) (1)
Mechanisms of autocrine and paracrine growth control in acute myelogenous leukemia. (1990) (1)
RESTORATIVE IMMUNOTHERAPY WITH INTERLEUKIN 2 (1985) (1)
Session IV: Autologous stem cell transplantation in hematologic malignancies: multiple myeloma (1999) (1)
Cancer: A Story of Stem Cells and Evolution (2015) (1)
Fibrinogen y-Chain mRNA Is Not Detected In Human Megakaryocytes (2003) (1)
106 High-dose therapy with etoposide, ifosfamide, carboplatin, and epirubicin (VIC-E) in non-small cell lung cancer (NSCLC) (1997) (1)
[Lambert-Eaton syndrome and Schwartz-Bartter syndrome in small cell bronchial cancer. Simultaneous manifestation of two paraneoplastic syndromes as an indication of a systemic malignant disease]. (1993) (1)
Dacarbazine and interferon-alpha for stage IV melanoma: 396 (1997) (1)
110 High-dose therapy with etopside, ifosfamide, carboplatin, and epirubicin (VIP-E) in small cell lung cancer (SCLC) (1997) (1)
A Textual Recommender System for Clinical Data (2018) (1)
[Blood stem-cell transplantation. Its current status and outlook]. (2008) (1)
Successful allogenic transplantation after autologous graft failure. (1994) (1)
The impact of cytokines on high dose chemotherapy followed by transplantation of purified and ex vivo expanded peripheral blood stem cells: achieving a state of minimal residual disease for tumor immunotherapy with cytokine gene transfected cells. (1995) (1)
Five years of sharing knowladge: The Journal of Science, Humanities, and Arts - JOSHA. (2020) (0)
DEMETRIOS PRIZE 2018 (2018) (0)
Visiting the atelier Carlos Cruz Diez, Paris. Un recorrido colorido por el Atelier Carlos Cruz Diez, Paris. (2018) (0)
JOSHA’S CRITICAL REVIEW OF “ Efficacy of Larotrectinib in TRK Fusion– Positive Cancers in Adults and Children (2018) (0)
Pilot study for the evaluation of T-cell-mediated tumor immunotherapy by cytokine gene transfer in patients with malignant tumors (1995) (0)
Treatment of relapsed non-Hodgkin’s lymphoma after BEAM chemotherapy and autologous transplantation by BU/CY chemotherapy and salvage transplantation (1997) (0)
IMBS Class 2017-19 Application Now Open (2016) (0)
Vectors for transfection of eukaryotic cells, their use and thus transfected target cells (1995) (0)
The JOSHA Demetrios Project: Monographs and Papers in any Language (2017) (0)
Mobilization of Peripheral Blood Progenitor Cells by Hematopoietic Growth Factors for Use in High-Dose Chemotherapy (1994) (0)
Placental Blood: New Options in Hematopoietic Stem Cell Transplantation (1997) (0)
[Proliferation and differentiation in megakaryopoiesis]. (1990) (0)
Artificial Intelligence and mathematical Models in Research and applied Oncology and Hematology (2021) (0)
Informing patients of relevant health information and innovations: patient recall or annual physical? (2018) (0)
marrow Patients receiving soybean lectin-separated and T cell-depleted bone mononuclear cells from patients after bone marrow transplantation: II. Interleukin-2 production and response to interleukin-2 by peripheral blood (2013) (0)
Apply by December 15th for the NEW IMBS Double Master Program in Biomedical Sciences: MSc from the University of Buenos Aires and MSc from Freiburg University (2017) (0)
Hematopoietic growth factors after hematopoietic cell transplantation: Are they useful? (2017) (0)
JOSHA`s CRITICAL REVIEW OF „Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer” (2018) (0)
Intrinsic Multidrug Resistance in Nude Mouse Xenografts: Immunocytochemical Detection of P-Glycoprotein and Chemoresistance In Vitro (1992) (0)
Case history. 1: the use of epoetin alfa in delayed anaemia. (1997) (0)
A Matched-pair Prospective Study On The Effect Of A Defined In-hospital Sports Program On Cognitive Functions In Patients Suffering From Cancer: 2286 (2009) (0)
IMBS Workshop “Science, Ethics and Society” open for registration! (2016) (0)
Recent Developments in the Ex Vivo Manipulation of Hematopoietic Cells from Bone Marrow and Blood (1997) (0)
Effect of purified human interleukin 2 on murine cytotoxic cell responses. Abstr. (1983) (0)
[Cytokines in tumor therapy]. (1988) (0)
Cytokines as Possible Effector Molecules in Human Cancer Therapy (1991) (0)
Presentation of chronic myelogenous leukemia as a rheumatoid syndrome--MRT-diagnosed chloroma. (1996) (0)
[Transfer RNA methyltransferases in different hemoblastoses]. (1973) (0)
Hematopoietic growth factors: American Society of Clinical Oncology utilization review (0)
Response to Interleukin-3 Treatment in Graft Failure After Bone Marrow Transplantation (1992) (0)
State-of-the-Art : balancing supportive care with emerging cancer therapies : full proceedings from a satellite symposium held at the 21st congress of the European Society of Medical Oncology (ESMO), Vienna, Austria, 3 November 1996 (1997) (0)
Cytotoxicity of TGF alpha-PE40 and correlation to expression of epidermal growth factor receptor. (1995) (0)
Harnessing knowledge AND clinical experience to improve patient care employing an electronic system analysing non-structured medical records: The “SimRec” Software (2019) (0)
Comprar Concise Manual of Hematology and Oncology | Andreeff, Michael | 9783540732761 | Springer (2008) (0)
Single-Center Retrospective Analysis of Prognosis of 138 Patients Older than 55 Years with Acute Myeloid Leukemia (2003) (0)
[Continuous delivery of epidermal growth factor to wounds in vivo by genetically modified fibroblasts transfected with a novel chimeric construct]. (1999) (0)
Hematopoietic Cytokines in Cancer Therapy: Concepts and First Clinical Observations (1989) (0)
RT-PCR for the Detection of Minimal Residual Disease in Acute Myeloblastic Leukemia with t(8;21) and t(15;17) (1998) (0)
Knowledge That is Not Communicated is Wasted: JOSHA - Open Access With Author Copyright - German Version: Nicht kommuniziertes Wissen wird verschwendet: JOSHA - Open Access With Author Copyright (2018) (0)
A process for the production of human, clonogenic fibroblasts method for Gentransfizierung of fibroblasts and fibroblasts thus obtained (1994) (0)
JOSHA’S CRITICAL REVIEW OF “GENE THERAPY IN PATIENTS WITH TRANSFUSION-DEPENDENT β-THALASSEMIA” BY A.A. Thompson et al. N Engl J Med 2018; 378:1479- 1493. (2018) (0)
[References for planning and implementation of clinical studies in the areas of somatic cell and gene therapy. German Society of Gene Therapy]. (1995) (0)
Modulation of Cytotoxicity and Differentiation-Inducing Potential of Cytosine Arabinoside in Myeloid Leukemia Cells by Hematopoietic Cytokines (1992) (0)
9. Cytokines and myeloid-specific genes: Patterns of expression and possible role in proliferation and differentiation of acute myelogenous leukemia cells (0)
Regulation of gene expression of macrophage-colony stimulating factor in human fibroblasts by the acute phase response mediators interleukin (IL)-1 beta, tumor necrosis factor-alpha and IL-6. (1998) (0)
Treatment of Philadelphia Chromosome Positive (Ph +) Chronic Myelogenous Leukemia in Blast Crisis and Ph + Acute Leukemia with High Dose Cytosine Arabinoside (HDARAC). (1991) (0)
CD34(+)- selected human peripheral blood progenitor cells Maintenance of transplantation potential in ex vivo expanded (2011) (0)
Author Correction: Learning deep features for dead and living breast cancer cell classification without staining (2021) (0)
[The effect of actinomycin d, acridine dyes and related substances on the biosynthesis of nucleic acids in normal and leukemic white blood cells. Comparative investigation in intact cells and in a cell-free system (author's transl)]. (1975) (0)
Diagnostic and Prognostic Significance of the CFU-c Assay in Acute Nonlymphoblastic Leukemia 1 (2006) (0)
A Novel Assay to Determine and Quantify the Regulation of Cell Motility and Migration Demonstrated on Hematopotetic Cells (1998) (0)
Metronomic doses and drug schematic combination response tested within chambered coverslips for the treatment of breast cancer cells (JIMT-1) (2022) (0)
[Interfering with research is unethical: DFG (Germany Research Committee) position on somatic cell and gene therapy]. (1995) (0)
Cytokines with possible clinical utility. (1987) (0)
Interleukin-2 Activates Nuclear Factor κB Binding Activity and Autoregulates Transcriptional Activity of its Own Receptor Gene by Normal Human Monocytes Engaging Nuclear Factor κB (1992) (0)
4908434 Process for preparing purified interleukin-2 (1990) (0)
Book reviews (2004) (0)
Effect Of A Defined In-hospital Sports Program On The Physical, Psychological And Sociological Aspects Of Patients Suffering From Cancer And Patients Suffering From Obesity: 1519 (2009) (0)
Interleukin 5 expressing allergen-specific T-lymphocytes in patients with dust mite sensitization: analysis at a clonal level. (1997) (0)
[In vitro and in vivo effects of recombinant human interleukin-3 on hematopoietic progenitor cells]. (1990) (0)
105 Correlation between expression of MDR1, GST-π, K-RAS, MDR3, CEA in human tumor xenografts (1995) (0)
New patent4778879 Highly purified human interleukin 2 and method (1989) (0)
Supportive Therapieprotokolle (2020) (0)
1st Freiburg,Germany - Mendoza, Argentina Symposium on Translational Medicine (2018) (0)
Frequent methylation of p15 5′ region in leukemic and preleukemic disorders, and reduction of p15 methylation levels by 5-aza-deoxycytidine treatment is correlated with clinical remission (1996) (0)
Pathophysiology of cytokines and therapeutic strategies in acute myeloid leukemia (1992) (0)
The JOSHA Demetrios Project: - Deutsch (2017) (0)
Evidence for Autostimulatory Mechanisms in Chronic Lymphocytic Leukemia. (2012) (0)
F and tumor necrosis factor-alpha factorneutrophils : role of granulocyte-macrophage colony-stimulating Inducible production of interleukin-6 by human polymorphonuclear (2003) (0)
“JOSHA’s Critical Review of ‘How to Regulate Evolving AI Health Algorithms’ by David W. Bates” (2023) (0)
Activation of NF-KB by Interleukin 2 in Human Blood 1 (2005) (0)
International Academy of Sciences, Humanities and Arts e.V. - Annual Report 2016 (2017) (0)
G-CSF and M-CSF: preclinical and clinical results. (1992) (0)
Stimulation of growth of human malignant lymphoma and lymphoid leukemia cells in vitro (1992) (0)
Cytokine gene therapy with gene transfected cells: Long term expression in vivo and therapeutic potential (1995) (0)
Methods for labeling of cells with this method, labeled cells, using the wild-type adeno-associated virus to label cells and test kits for the detection of the wild-type adeno-associated virus in cells (1993) (0)
Hematopoietins: New Tools in the Treatment of Hematopoietic Insufficiency (1993) (0)
QUANTITATION OF CD34+ CELLS. REPLY (1992) (0)
DEMETRIOS PRIZE 2019 (2019) (0)
Demetrios Award 2020 (2020) (0)
Ex Vivo Culture and Expansion of Haematopoietic Progenitor Cells in Cancer Patients (1997) (0)
In Vivo Efficacy of Peptide-Derived B Cell Receptor (BCR) Targeted Therapy In a Disseminated Burkitt′s Lymphoma Xenograft Modell (2010) (0)
Scientific Proceedings Second International Symposium on Cytostatic Drug Resistance (1991) (0)
DEMETRIOS PRIZE 2019. The winners! (2019) (0)
4925919 Purified interleukin 2 (1990) (0)
Standardized Treatment Protocols (2008) (0)
Unravelling the syndrome of age associated diseases 2: Targeting autoimmunity with anti-CD20 antibodies to reduce age-associated diseases (2019) (0)
Haematopoietic Growth Factors: Therapeutic Uses (2006) (0)
[Guidelines for standardized diagnosis, therapy and after-care of thyroid cancer]. (1997) (0)
Fibroblasts containing a foreign gene composition for the treatment of wounds (1997) (0)
Circadian variation of alpha- amanitine sensitive RNA-synthesis in normal human lymphocytes. (1976) (0)
Induction and large scale expansion of CD8+ tumor-specific CTL by in vitro stimulation with CD80- transfected autologous melanoma cells (1997) (0)
[DNA directed nucleic acid polymerases in normal and pathologic human leukocytes: differentiation, characterization and purification of DNA polymerases I, II and RNA polymerases A, B and their in vitro influence by cytostatics]. (1973) (0)
[Gene therapy. A realistic approach to treating malignant diseases?]. (1997) (0)
The 1971 War on Cancer Revisited (2016) (0)
[Free and template-bound RNA polymerase in normal and leukaemic human lymphocytes (author's transl)]. (1976) (0)
GEMA—An Automatic Segmentation Method for Real-Time Analysis of Mammalian Cell Growth in Microfluidic Devices (2022) (0)
The Principles of Cancer: A Metaphor of Life? (2019) (0)
[False diagnosis of "osteoporosis" in diffuse multiple myeloma (author's transl)]. (1977) (0)
[DNA directed nucleic acid polymerases in normal and pathologic human leukocytes: increased specific activities and different kinetics of RNA polymerase B in cell nuclei of pathological cells]. (1973) (0)
[References for planning and implementation of clinical studies in somatic cell and gene therapy]. (1995) (0)
Purification and biochemical characterization of human pluripotent hematopoietic colony-stimulating factor ( protein purfcation / heatopoietlc sem cells ) (2003) (0)
Favourable outcomes of double‐hit/double‐expressor lymphoma and high‐grade B‐cell lymphoma, not otherwise specified after early dose‐intensive treatment and up‐front autologous stem cell transplantation: a single‐centre retrospective experience (2022) (0)
The clinical role of growth factors in the treatment of breast cancer. (1998) (0)
Monoklonale Anti-Interleukin-2-Antikörper (1983) (0)
Bright minds for a better world! Demetrios Prize 2019 (2019) (0)
Synergism of Hematopoietic Cytokines and Cytosine Arabinoside in the Treatment of Acute Myelogenous Leukemia: Experimental Rationales (1992) (0)
Assay for Leukemia Differentiation Induction (2003) (0)
[Malignant tumors of the soft tissue and the peripheral nervous system (soft tissue sarcomas). Current aspects of diagnosis and therapy]. (1978) (0)
IMBS Symposium "Science, Ethics and Arts" open for registration! (2016) (0)
Metronomic doses and drug schematic combination response tested within microfluidic models for the treatment of breast cancer cells (JIMT-1) (2020) (0)
JOSHA`s Critical Review of: “Systematic reanalysis of clinical exome data yields additional diagnoses: implications for providers”: IS THERE A NEED FOR “RECALL” IN CLINICAL MEDICINE? (2018) (0)
Knowledge That is Not Communicated is Wasted: JOSHA - Open Access With Author Copyright (2018) (0)
Unraveling the syndrome of age-associated diseases: Common pathways and novel therapeutic strategies (2019) (0)
Interleukin 2: Biology, Pathophysiology, and Clinical Possibilities (1987) (0)
Somatic Gene Therapy in Cancer (1997) (0)
Subject and method of preferred transient expression and possible translation of specific RNA in the cytoplasmic region of higher eukaryotic cells (1995) (0)
Case history. 2: The use of epoetin alfa before high-dose chemotherapy. (1997) (0)
Hematopoietic Ex Vivo Gene Transfer (1998) (0)
The JOSHA Demetrios Project: - English (2017) (0)
DEMETRIOS - PRIZE 2018. The winners. (2018) (0)
Scientific Europe Turns Into a Fair Mode: Open Access Journals Reducing The Cost of Knowledge (2018) (0)
interferon-gamma, and erythropoietin cells by stem cell factor, interleukin-1 beta (IL-1 beta), IL-6, IL-3, Ex vivo expansion of enriched peripheral blood CD34+ progenitor (2011) (0)
THE CLINICAL ROLE OF HEMATOPOIETIC GROWTH FACTORS IN PERIPHERAL BLOOD PROGENITOR CELL TRANSPLANTATION (1994) (0)
B-Cell Receptor Profiling Suggests a Limited Number of Antigens Involved in the Pathogenesis of Chronic Lymphocytic Leukemia. (2008) (0)
Brief an die Herausgeber · Letter to the Editors (2009) (0)
Erratum: Interleukin-4 inhibits growth of multiple myelomas by suppressing interleukin-6 expression (Blood (1991) 78 (2070)) (1999) (0)
TNF-α, IL-6, and Phorbol Ester but Not G-, M-, GM-CSF, IL-3, and IL-4, Induce Monocytic Differentiation and Modulate Expression of c-fos, c-fms , and c-myc in the Human Monoblast Line THP-1 (1990) (0)
[DNA-dependent RNA polymerases in human leukocytes. II different specific activities of the polymerases A and B in acute and chronic leukemia and their prognostic relevance (author's transl)]. (1975) (0)
4908433 Uses of interleukin-2 (1990) (0)
[Implantation of fetal thymus tissue in patients with progressive malignant neoplasms (author's transl)]. (1974) (0)
Coexpression of Interleukin 2 and HTLY III Messenger RNA in Patients with Acquired Immune Deficiency Syndrome (1989) (0)
Low-Dose Aclacinomycin and Intermediate-Dose Cytosine Arabinoside in Relapsed and Refractory Acute Myelogenous Leukemia (1990) (0)
Abnormalities in Interleukin 2 Production and Response in Cancer and Possible Therapeutic Approaches (1986) (0)
Recombinant human hematopoietic growth factors in clinical oncology (1991) (0)
Ionizing radiation induces IL-6-production by human fibroblasts involving activation of nuclear factor-. kappa. B (1992) (0)
interleukin-6 expression Interleukin-4 inhibits growth of multiple myelomas by suppressing (0)
High-dose chemotherapy and autologous hematopoietic stem cell transplantation in patients with second primary malignancies. (1997) (0)
Purification d'interleukine-2 (1983) (0)
Proliferation of hematopoietic progenitor cells ex vivo and to compositions of hematopoietic growth factors (1992) (0)
Synergism Between Cyclophosphamide and Interleukin-2 (2018) (0)
B-Cell Receptor Recognition of Multiple Epitopes Correlates with An Aggressive Clinical Course of Chronic Lymphocytic Leukemia. (2009) (0)
Interleukin-2 in the Treatment of Malignant Melanoma and Renal Cell Carcinoma (1989) (0)
TdT activity in B cell ALL. (1978) (0)
Chemotherapy for Adult Acute Myeloid Leukemia: Study Results from the Acute Myeloid Leukemia Cooperative Group and Overview (1993) (0)
ifosfamide, and cisplatin (see comments) stimulating factor following polychemotherapy with etoposide, administration of interleukin-3 and granulocyte-macrophage colony- Mobilization of peripheral blood progenitor cells by sequential (2011) (0)
XXIII International Association for Comparative Research on Leukemia and Related Diseases Symposium: from molecular pathogenesis to targeted therapy in leukemia and solid tumors. (2008) (0)
Soluble tumor necrosis factor receptors are released independent of TNF in endotoxemia (1995) (0)
Wilsede-Schule für Onkologie und Hämatologie – Wilsede School for Oncology and Hematology (1995) (0)
TdT activity in B cell ALL [letter] (1978) (0)
leukemic human megakaryoblasts Interleukin-6 (IL-6) is an intermediate in IL-1-induced proliferation of (2010) (0)
Non-Hodgkin-Lymphome (NHL) (2020) (0)
[Molecular medicine--from genes to therapy]. (1997) (0)
Tumor Immunotherapy by IL-2 and IL-2 Gene Transfected Cells (1996) (0)
Book reviews (2004) (0)
Hematopoietic growth factors in peripheral blood progenitor cell transplantation (1994) (0)
Freiburg IMBS Winter School Biomedical Sciences 2018-19 Now Open for Registration (2018) (0)
[Hematopoietins: a new agent for the treatment of hemopoietic insufficiency]. (1990) (0)
The management of primary mediastinal B-cell lymphoma with sclerosis (1994) (0)
Kongressbericht – Congress Report (1995) (0)
Evaluation of the Risk of Relapse and Survival Using a Conditional Survival Approach in 815 Multiple Myeloma Patients (2016) (0)
Knowledge That is Not Communicated is Wasted: JOSHA - Open Access With Author Copyright - Chinese Version: 没有被传播的知识被浪费：JOSHA - 与作者版权的开放访问 (2018) (0)

This paper list is powered by the following services:

Other Resources About Roland Mertelsmann

en.wikipedia.org

What Schools Are Affiliated With Roland Mertelsmann?

Roland Mertelsmann is affiliated with the following schools: